Jianxin Wang1,2, Dongliang Yan2, Kuixiang Liang3, Zhonghua Xu4. 1. Department of Urology, Qilu Hospital, Shandong University, No. 107 Wenhua Xi Road, Jinan, 250000, Shandong, China. 2. Department of Urology, Affiliated Hospital of Binzhou Medical University, Binzhou, 256603, China. 3. Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University, Binzhou, 256603, China. 4. Department of Urology, Qilu Hospital, Shandong University, No. 107 Wenhua Xi Road, Jinan, 250000, Shandong, China. zg9800@163.com.
Abstract
OBJECTIVE: To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5). RESULTS: After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group, respectively. Furthermore, no significant difference in NIH-CPSI scores was observed between IIIA and IIIB patients in each arm. Levofloxacin alone or levofloxacin plus terazosin could significantly reduce EPS-WBC counts compared with terazosin alone. Finally, no significant difference was found between the three arms in terms of IIEF-5 scores. CONCLUSION: A 6-week short-term treatment of levofloxacin or levofloxacin plus terazosin was more effective than terazosin alone in patients with category III CP/CPPS. Furthermore, levofloxacin treatment was not different from levofloxacin plus terazosin treatment in terms of treatment effect.
RCT Entities:
OBJECTIVE: To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5). RESULTS: After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group, respectively. Furthermore, no significant difference in NIH-CPSI scores was observed between IIIA and IIIB patients in each arm. Levofloxacin alone or levofloxacin plus terazosin could significantly reduce EPS-WBC counts compared with terazosin alone. Finally, no significant difference was found between the three arms in terms of IIEF-5 scores. CONCLUSION: A 6-week short-term treatment of levofloxacin or levofloxacin plus terazosin was more effective than terazosin alone in patients with category III CP/CPPS. Furthermore, levofloxacin treatment was not different from levofloxacin plus terazosin treatment in terms of treatment effect.
Authors: T E Bjerklund Johansen; R N Grüneberg; J Guibert; A Hofstetter; B Lobel; K G Naber; J Palou Redorta; P J van Cangh Journal: Eur Urol Date: 1998-12 Impact factor: 20.096